Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906497 · ClinicalTrials.gov registry record · Phase 4
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
A Phase 4 study of Atopic Dermatitis, sponsored by Johann E Gudjonsson MD PhD.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT06906497 is a Phase 4 study of Atopic Dermatitis that is actively recruiting participants, run by Johann E Gudjonsson MD PhD. The registered enrollment target is 48 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06906497, a Phase 4 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Johann E Gudjonsson MD PhD.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.
Conditions Studied
Interventions
- DRUG lebrikizumab
Study Locations (4)
Other
- University of Freiburg - Freiburg im Breisgau
- Lausanne University Hospital - Lausanne
California
- Physioseq USA - CA - Folsom
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2027-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06906497
The ClinicalTrials.gov registry entry for NCT06906497 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (92% lower). The listed sponsor is Johann E Gudjonsson MD PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which lebrikizumab is the first listed.
NCT06906497 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT06906497 about?
NCT06906497 is a clinical study titled "Lebrikizumab in Moderate-to-severe Atopic Dermatitis". This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.
What is the current status of trial NCT06906497?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2025-07-02. Estimated completion is 2027-07.
What conditions does trial NCT06906497 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06906497?
The interventions under investigation include: lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT06906497?
This trial is sponsored by Johann E Gudjonsson MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06906497 being conducted?
This trial has 4 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
RECRUITING · Phase 4
-
Molecular Signatures of Cutaneous Dupilumab Response
RECRUITING · Phase 4
-
Ethnic Differences in Mechanisms of Action of Dupilumab
RECRUITING · Phase 4
-
Dupixent and Narrowband UVB for Atopic Dermatitis
RECRUITING · Phase 4
-
Dupilumab De-escalation in Pediatric Atopic Dermatitis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.